08 June 2026
08 June 2026
Roche believes its new BTK-degrader bexobrutideg will outperform approved BTK-inhibitors in B-cell malignancies.
Key obesity data from Eli Lilly, Boehringer Ingelheim and Sciwind Biosciences captivated ADA 2026 attendees.
The authorisation covers combination use with miglustat, or as a single therapy if miglustat cannot be tolerated.
The partnership includes a five-year licence for Owkin’s K Pro, an AI platform designed to augment drug discovery.
The Regeneron-partnered biotech is currently progressing its lead asset, zolucatetide, in desmoid tumours.
In this episode, two oncology analysts share their insights from the ASCO show floor, while talking through the readouts that excited them most.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
